What GLP-1 Does CVS Caremark Cover? 2026

Affiliate disclosure: The RX Index may earn a commission from some provider links on this page. Clicking a link does not change your plan benefits or your medication cost.

What GLP-1 does CVS Caremark cover? Its July 2026 public commercial lists include Wegovy and weight-management liraglutide for obesity, plus liraglutide, Mounjaro, Ozempic, Rybelsus, and Trulicity for diabetes. Its October 1 Standard Control list adds Zepbound, Foundayo, and Wegovy HD. Your plan can customize or exclude coverage.

Public-template question	Verified answer
What is listed for weight management now?	Wegovy and weight-management liraglutide on the reviewed July lists
What changes October 1, 2026?	The future Standard Control list adds Zepbound, Foundayo, and Wegovy HD
What is the biggest published weight-management PA gate?	Six months of documented comprehensive-program history under the Wegovy, Zepbound, and Foundayo standard criteria
What decides your real coverage?	Your member plan, exact drug and form, indication, restrictions, and claim-level cost

That's the short version. Here's the part almost nobody tells you, and it's the part that decides most cases:

The documented medical reason can change the rules as much as the drug and form.

Same plan. Same drug. One indication can carry a six-month program gate. Another indication can skip it. The published initial approval windows range from six to 12 months.

We read CVS Caremark's current and future drug lists and four published approval policies side by side. We'll show you the five decision paths, the paperwork attached to each one, and the exact five-minute check that turns a public answer into your plan's answer.

Who this page is for

This page is for you if:

Your pharmacy card says CVS Caremark and you want to know which exact drug and form to search in your plan portal
You got denied and don't understand why
You're on Zepbound, or want to be, and you're tracking the October 1 change
Your plan says one thing and a friend's plan says another

This page can't tell you:

Your exact copay
Whether your employer included weight-loss drug coverage
Whether your specific request will be approved
Rules for Medicare, Medicaid, or FEHB plans that use Caremark — those require their own plan documents

If you have Medicare, stop here: use your Medicare plan's formulary and Evidence of Coverage instead. The commercial templates analyzed below are not the right documents for that decision.

What GLP-1 does CVS Caremark cover right now?

Answer: The July 1, 2026 public Standard Control and Value lists identify Wegovy and weight-management liraglutide in the anti-obesity category. They identify liraglutide, Mounjaro, Ozempic, Rybelsus, and Trulicity in the diabetes category. Zepbound, Foundayo, and Wegovy HD appear on the future Standard Control list effective October 1, 2026. Your member plan can differ.

First, two words you'll see everywhere on this page:

PBM (pharmacy benefit manager) — the company that administers the drug side of a health plan. CVS Caremark is one. It builds formulary templates and processes pharmacy claims. It is not necessarily the company that insures or funds your benefits.
Formulary — the drug list and restriction structure a plan uses. CVS Caremark publishes standard versions, but a plan sponsor can customize coverage.

Here is the full current-versus-future map we assembled from the July Standard Control list, the July Value Formulary, the October Standard Control list, and Caremark's published PA policies.

Drug or form	Treatment lane	July 2026 Standard Control	July 2026 Value Formulary	October 1 Standard Control	Published Caremark PA policy
Wegovy injection	Weight management; cardiovascular-risk reduction; MASH	WEGOVY listed; form not separated	Injection listed	WEGOVY listed	4774-C
Wegovy tablets	Adult weight management; cardiovascular-risk reduction	WEGOVY listed; form not separated	Tablets listed	WEGOVY listed	4774-C
Wegovy HD	Adult weight management	Not located	Not located	Listed	4774-C
Liraglutide (weight management)	Weight management	Listed by generic name	Listed by generic name	Listed by generic name	Exact member-plan criteria must be checked
Zepbound	Weight management; obstructive sleep apnea	Not in the current anti-obesity section; appears in the removed-products alternatives material	Not located in the reviewed PDF	Listed	6192-C
Foundayo	Adult weight management	Not located	Not located	Listed	7433-C
Liraglutide	Type 2 diabetes	Listed by generic name	Listed by generic name	Listed by generic name	2439-C covers Victoza among its named products
Mounjaro	Type 2 diabetes	Listed	Listed with step therapy, quantity limits, and conditional PA if step requirements are not met	Listed	2439-C
Ozempic injection	Type 2 diabetes; cardiovascular and kidney-risk indications in diabetes	Listed	Listed with step therapy, quantity limits, and conditional PA if step requirements are not met	Listed	2439-C
Rybelsus	Type 2 diabetes; cardiovascular-risk indication in diabetes	Listed	Listed with step therapy, quantity limits, and conditional PA if step requirements are not met	Listed	2439-C
Trulicity	Type 2 diabetes; cardiovascular-risk indication in diabetes	Listed	Listed with step therapy, quantity limits, and conditional PA if step requirements are not met	Listed	2439-C
Byetta, Bydureon BCise, Victoza, and Ozempic tablets	Type 2 diabetes	Not found as preferred entries in the reviewed current Standard list	Not found in the reviewed current Value incretin section	Member plan must be checked	Named in 2439-C; policy inclusion does not prove formulary coverage

Sources: CVS Caremark's July 2026 Standard Control list, July 2026 Value Formulary, October 1, 2026 Standard Control list, and published criteria 4774-C, 6192-C, 7433-C, and 2439-C.

Download the August 2026 coverage map as CSV.

How to read the status words

Listed means we found the drug in that exact public document.
Not located means we did not find the drug name in the reviewed public list. It does not prove that every custom plan excludes it.
Scheduled means CVS Caremark published a future effective date or future-dated list.
Published PA policy means CVS Caremark has a standard criteria document. It does not prove that your member plan covers the drug or uses that exact policy.

One important word about that table. When we say a drug is "listed," we mean we found it in Caremark's published standard drug list. When a drug isn't there, we say "not located" — not "excluded." Those are different things. A public list is a template. Your employer can add drugs to it, take drugs off it, or throw the whole category out. We'll only tell you what the documents actually prove.

The July Value Formulary also matters because it exposes a flaw in the blanket claim that every listed GLP-1 automatically requires prior authorization. The diabetes entries carry step-therapy and conditional-PA markers. The anti-obesity entries on the reviewed page do not show a PA marker. That does not prove your plan skips PA; it proves the public file does not support a universal statement. Check the member portal.

Why did your coworker with the same CVS Caremark card get a different answer?

Answer: CVS Caremark coverage runs through three separate gates. Your plan sponsor decides whether weight-management drugs are part of the benefit, your member formulary decides which products and forms are listed, and utilization-management rules decide whether the request meets the plan's criteria. A category exclusion cannot be fixed by switching from one weight-management drug to another.

This is the section that saves people the most time, so we put it early.

Two people can hold identical CVS Caremark cards and get completely different answers. That's not a mistake. It's how the system is built.

Gate 1: Your employer or plan sponsor

Your employer — or your union, or whoever pays for your plan — decides whether weight-management medications are part of the drug benefit at all.

CVS Health says this out loud. In its May 28, 2026 announcement, the company said plan sponsors that adopt its template formularies retain discretion to customize member coverage.Source 4

If your plan left weight-management drugs out, switching from Wegovy to Zepbound will not create a weight-management benefit. A drug-level PA cannot override a category that the plan did not include. Ask whether the plan offers a formal benefit appeal or exception, but do not assume more chart notes will solve a plan-design exclusion.

Gate 2: Your member formulary

If weight management is in your benefit, the next question is whether your specific drug and form are on your specific list.

The public Standard Control and Value documents are baselines, not your contract. Your plan may use one, customize one, or apply a different design.

If your drug isn't on your list, ask whether the plan offers a formulary exception and what evidence the exception requires. Do not assume an exception exists or that it follows the same rules as a normal PA.

Gate 3: The approval rules

This is prior authorization — a review your plan runs before it agrees to pay under the requested criteria. Your doctor sends in your records. Someone checks them against the plan's written requirements.

A request can fail here because a required diagnosis, lab result, baseline measurement, treatment history, or program record was not documented. It can also fail because the member's actual criteria differ from the public standard policy.

And then a fourth question

Even after all three gates say yes, you still have to ask: what will it cost me? Covered doesn't mean cheap. We'll get to that.

The question	What it's really asking	Who controls it	Best next move
Is it in my benefit?	Did the plan include weight-management drug coverage?	Your employer or plan sponsor	Ask HR or benefits for the governing plan language and any formal appeal or exception process
Is it on my list?	Is this exact drug and form on my member formulary?	Your member plan and formulary design	Search the member portal; ask about a formulary exception if it is non-listed
Will they approve me?	Does the request meet the member-plan criteria?	The plan's utilization-management process	Obtain the exact criteria and match the submission to the actual missing item
What will I pay?	What do tier, deductible, coinsurance, pharmacy, and day supply produce?	Your plan design and claim details	Get a dated estimate for the exact drug, form, pharmacy, and supply

What this page can't do — straight up. We can't tell you your copay, and we can't promise your request will go through. Your employer's benefit design is a private contract. No website has the complete answer, including CVS Caremark's own public documents. What we can do is narrower and a lot more useful: show you exactly what appears on the public lists, what Caremark's own written policies require, how the documented indication changes the paperwork, and a five-minute way to get a real answer from your own plan. That's the part everyone else skips.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

The right GLP-1 provider isn't the same for everyone — it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred form (injection or oral), and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose.

→ Get my personalized GLP-1 action plan — free, 60 seconds, no account.

Before you go further, do one thing. Log in at Caremark and search your exact drug and form in the Check Drug Cost and Coverage tool. Takes two minutes. Screenshot whatever it says. Every section below will make more sense once you have that screen in front of you.

→ Check my CVS Caremark drug cost and coverage (Caremark's own member site — not an affiliate link)

What changed June 1, and what changes October 1, 2026?

Answer: CVS Caremark removed its new-to-market block on Foundayo effective June 1, 2026, where plans approve coverage. Its future Standard Control list adds Zepbound, Foundayo, and Wegovy HD to the anti-obesity category on October 1, 2026. Wegovy and weight-management liraglutide remain listed. Plan sponsors still control adoption and customization.

Date	What the primary source establishes	What it does not establish
April 1, 2026	FDA-approved Foundayo for adult chronic weight management; the tablet can be taken once daily with or without food	That any particular plan covers it
June 1, 2026	CVS removed Foundayo's new-to-market block where plans approve coverage	Universal Caremark coverage beginning June 1
July 1, 2026	The reviewed current public lists show Wegovy and weight-management liraglutide in anti-obesity; Zepbound and Foundayo are not listed there	Your custom member plan's exact result
October 1, 2026	The future Standard Control list adds Zepbound, Foundayo, and Wegovy HD	That every sponsor adopts weight-management coverage or every request is approved

Sources: CVS Caremark's May 28 announcement, July Standard Control list, October Standard Control list, and the FDA-approved Foundayo label.

What the October change does — and doesn't do

Zepbound comes back as an additional preferred option in CVS Caremark's announced commercial-formulary strategy. Not a replacement. The future Standard Control list still includes Wegovy and adds Wegovy HD and Foundayo.Source 3 Source 4

Here's what it does not do: it does not make Zepbound covered for you. Your employer or plan sponsor still chooses whether weight-management drugs are in the benefit. Your member plan may still require prior authorization, step therapy, quantity limits, or another restriction. "Listed October 1" is a public-template fact, not a promise to an individual.

If you're on Zepbound now — or you were, and you switched — put October 1 on your calendar as a check date, not a start date. Ask your plan whether the update is loaded into your member benefit and whether a new PA is required.

Want the deep version of the Zepbound question specifically? Read Does CVS Caremark cover Zepbound?

Which GLP-1 does CVS Caremark cover for type 2 diabetes?

Answer: The current July public Standard Control and Value lists identify liraglutide, Mounjaro, Ozempic injection, Rybelsus, and Trulicity in the diabetes incretin category. Caremark's published standard PA policy 2439-C covers a broader named set, including Byetta, Bydureon BCise, Victoza, and Ozempic tablets. Policy inclusion is not proof of member-formulary coverage. The policy's approval duration is 12 months.

This is the half of the question most pages skip entirely. It shouldn't be.

We pulled Caremark's diabetes policy and read it end to end. Here's what it actually requires under the published standard criteria.

Public formulary status and PA-policy status are not the same thing

Product	Found in current July public diabetes lists?	Named in published PA policy 2439-C?	What the combination means
Liraglutide	Yes, by generic name	Victoza is named	Check the member portal for the exact covered product and form
Mounjaro	Yes	Yes	Public baseline supports listing; member restrictions still control
Ozempic injection	Yes	Yes	Public baseline supports listing; member restrictions still control
Rybelsus	Yes	Yes	Public baseline supports listing; member restrictions still control
Trulicity	Yes	Yes	Public baseline supports listing; member restrictions still control
Byetta, Bydureon BCise, Victoza, Ozempic tablets	Not found as preferred entries in the reviewed current public sections	Yes	The policy tells you criteria exist; it does not prove the member plan lists the product

The two hurdles in the published initial diabetes pathway

For an initial request, policy 2439-C first distinguishes a new start from continuation: the initial pathway says the patient has not been receiving a stable maintenance dose of one of the covered drug classes for at least three months. The continuation pathway uses the opposite condition. The two evidence hurdles below then decide whether the documented diagnosis and an additional branch are present.

Hurdle one — document the diagnosis. The standard policy asks for one of these documented historical results:

A1C of 6.5% or higher
Two-hour plasma glucose of 200 mg/dL or higher on an oral glucose-tolerance test
Symptoms of hyperglycemia or hyperglycemic crisis plus a random plasma glucose of 200 mg/dL or higher
Fasting plasma glucose of 126 mg/dL or higher after at least an eight-hour fast

"My doctor said I'm diabetic" isn't enough. They need the number in the chart.

Hurdle two — meet one additional branch. The standard policy then asks for one of these:

Metformin produced an inadequate response, was not tolerated, or is contraindicated
Combination therapy is required and A1C is 7.5% or higher
The patient has MASLD or MASH
One of the product-specific cardiovascular or kidney branches below applies

That last bullet is where it gets interesting.

Caremark's diabetes policy names specific products for specific conditions

Read the criteria closely and something jumps out. Several requirements don't just say "a GLP-1." They name particular drugs. Here's what we found when we mapped them:

If the documented condition is…	The published standard policy names…	What this is
Established cardiovascular disease	Trulicity, Ozempic injection, or Victoza	An administrative PA branch, not a treatment ranking
Chronic kidney disease	Ozempic injection	An administrative PA branch
Advanced chronic kidney disease, eGFR under 30 mL/min/1.73 m²	Trulicity or Victoza	An administrative PA branch
Multiple cardiovascular risk factors	Trulicity	An administrative PA branch
High risk of a major cardiovascular event	Rybelsus or Ozempic tablets	An administrative PA branch
MASLD or MASH with type 2 diabetes	Any product covered by the policy can use this branch	A general administrative branch

Mounjaro is named on none of them.

To be clear about what that means and what it doesn't: this is not a statement about how well Mounjaro works. It's what Caremark's own published approval criteria say. The standard policy can still support Mounjaro through the metformin, combination-therapy, or MASLD/MASH branches when the full criteria are met.Source 8

Practical takeaway: if you have type 2 diabetes and kidney disease, the published standard policy names Ozempic injection in the CKD branch. Bring the actual policy to your prescriber so the office can inspect the right administrative criteria. That is not a medical recommendation, and it does not guarantee approval.

If you have diabetes and heart disease, there's a handoff

Here's a detail that only shows up if you read two Caremark documents side by side.

Wegovy's heart-protection path requires that the patient does not have type 2 diabetes. The policy then points to Ozempic as the diabetes cardiovascular-risk product.Source 5

Then the diabetes policy lists Ozempic injection as a named option for established cardiovascular disease in type 2 diabetes.Source 8

Two separate documents, one clean handoff. If you have both conditions, Caremark's standard paperwork points to the diabetes policy and names Ozempic injection. We're connecting those two lines so your doctor's office can inspect the right criteria before submitting.

One thing this section is not

A diabetes drug on the formulary is not proof your plan will pay for it as a weight-loss treatment. Different lane, different rules. Please don't read this section as a workaround, and don't ask a clinician to document a diagnosis you do not have. The request should match the real medical record and the prescriber's judgment.

Which GLP-1 does CVS Caremark cover for weight loss?

Answer: The July public commercial lists identify Wegovy and weight-management liraglutide in the anti-obesity category. The future October 1 Standard Control list adds Zepbound, Foundayo, and Wegovy HD. Caremark also publishes standard PA policies for Wegovy, Zepbound, and Foundayo, but the existence of a policy does not guarantee that your member plan covers the product or requires that exact PA.

Wegovy is the clearest current public-template option

If you're asking "which weight-management GLP-1 is plainly visible in the current public files today," it's Wegovy. The current Standard Control list names WEGOVY, and the current Value Formulary separately lists Wegovy injection and tablets.Source 1 Source 2

Wegovy comes in forms that do not have identical FDA indications or published Caremark rules:

Wegovy injection — a weekly injection. The current label includes chronic weight management in adults and patients 12 and older, cardiovascular-risk reduction in qualifying adults, and noncirrhotic MASH with F2–F3 fibrosis in adults.
Wegovy tablets — a daily tablet. The current label includes adult chronic weight management and cardiovascular-risk reduction. It does not include the pediatric or MASH indications listed for the standard injection.
Wegovy HD — a 7.2 mg injection named in Caremark policy 4774-C and in the future October Standard Control list. The published policy excludes Wegovy HD from the cardiovascular-risk and MASH paths.Source 3 Source 5 Source 9

When you search your plan's portal, search the exact form. "Wegovy" and "Wegovy tablets" can return different results.

Foundayo — the new pill

Foundayo (orforglipron) was FDA-approved on April 1, 2026 for adults with obesity, or overweight with at least one weight-related condition. It's a once-daily pill that can be taken with or without food.Source 11

CVS Caremark removed its new-to-market block on June 1, 2026. Removing it clears the way — where a plan approves coverage.Source 4

That last phrase is doing real work. It means the central block was removed for plans that approve the drug, not that every member automatically gained coverage. Foundayo does appear on Caremark's October Standard Control list, and Caremark has published PA policy 7433-C. Between June and October, your member plan is the only source that can answer whether it is covered now.Source 3 Source 7

Weight-management liraglutide and the non-GLP-1 alternatives

Caremark's public July lists name liraglutide (weight management) rather than the Saxenda brand in the preferred anti-obesity line. Your member portal must identify the exact product and NDC your plan recognizes.

The reviewed current lists also include orlistat and Qsymia or generic phentermine-topiramate in the anti-obesity category. They are not GLP-1 medications. Their presence matters because a member plan may present them as alternatives, but the public list alone does not tell you whether they are medically appropriate or cheaper for you.

Does CVS Caremark require six months of weight-management records?

Answer: Caremark's published standard weight-management criteria for Wegovy, Zepbound, and Foundayo require a comprehensive program with behavior change, reduced-calorie diet, increased physical activity, and continuing follow-up for at least six months before drug therapy. That gate does not appear in the published cardiovascular-risk, obstructive-sleep-apnea, MASH, or type 2 diabetes paths reviewed here.

This is the most useful thing on this page. Read it twice.

Caremark's published weight-management criteria contain a requirement many patients do not know to ask about and a submission can miss unless the chart shows it:

“for at least 6 months prior to using drug therapy.”

Six months. Before the medication. Documented.

We found that gate in the Wegovy criteria (4774-C), Zepbound criteria (6192-C), and Foundayo criteria (7433-C).Source 5 Source 6 Source 7

Why this is where requests die

Picture how it usually goes. You see your doctor. They agree a GLP-1 makes sense. Their office sends the request. Three weeks later it comes back: criteria not met.

Nobody lied. Nobody made a mistake exactly. The submission may simply have failed to show the six-month program history the published policy asks for.

The good news, and it's real

You may already have records that matter and not know it.

If you've been working with your doctor on weight for six months — regular visits, weigh-ins, diet conversations, activity advice — that may already be in your chart. A dietitian, hospital program, or other structured follow-up may also have records worth gathering.

Caremark's published criteria don't give a complete list of acceptable proof. So don't guess. Call and ask: "What documentation of a six-month comprehensive weight-management program will you accept under my exact plan?" Then get that specific evidence into the chart before the request goes in.

Fixing this before submission is enormously easier than appealing after.

How do CVS Caremark's five GLP-1 approval paths differ?

Answer: The documented indication changes the published requirements as much as the product. Chronic weight-management requests carry the six-month program gate; cardiovascular-risk, obstructive-sleep-apnea, MASH, and type 2 diabetes paths do not. The standard initial approval windows range from six months for Wegovy tablets to 12 months for cardiovascular-risk, MASH, and diabetes requests.

Here's the whole thing in one table. This is what we built by reading Caremark's four published criteria documents side by side.

The reason on the request	Drug or form	Six-month program?	Published BMI rule	Published standard initial approval	Key documentation named in the policy
Adult weight management	Wegovy standard injection	Yes	Baseline 30+, or 27+ with one related condition	8 months	Program history, baseline BMI, and the related condition when BMI is 27–29.9
Adult weight management	Wegovy HD injection	Yes	Baseline 30+, or 27+ with one related condition	8 months	Program history, baseline BMI, and the related condition when BMI is 27–29.9
Adult weight management	Wegovy tablets	Yes	Baseline 30+, or 27+ with one related condition	6 months	Program history, baseline BMI, and the related condition when BMI is 27–29.9
Adult weight management	Zepbound	Yes	Baseline 30+, or 27+ with one related condition	8 months	Program history, baseline BMI, and the related condition when BMI is 27–29.9
Adult weight management	Foundayo	Yes	Baseline 30+, or 27+ with one related condition	8 months	Program history, baseline BMI, and the related condition when BMI is 27–29.9
Cardiovascular-risk reduction	Wegovy standard injection or tablets; Wegovy HD excluded	No	Baseline 27+	12 months	Established cardiovascular disease, no type 2 diabetes, and guideline-directed therapy or a documented reason not to receive it
Moderate-to-severe obstructive sleep apnea	Zepbound	No	Current BMI 30+	6 months	AHI of at least 15 on PSG or an adequate home sleep-apnea test
Noncirrhotic MASH with F2–F3 fibrosis	Wegovy standard injection only; Wegovy HD and tablets excluded	No	No BMI threshold stated	12 months	F2–F3 fibrosis confirmed by an accepted noninvasive assessment or historical biopsy; gastroenterology or hepatology involvement
Type 2 diabetes	Products named in 2439-C	No	No BMI threshold	12 months	Qualifying A1C or glucose history plus one additional policy branch

Important: Those are the durations in the published standard policies, not a promise that your member plan uses them. Retrieve the criteria attached to your actual benefit before calendaring a renewal.

A few terms in there, defined:

PAD — peripheral artery disease. The published cardiovascular path counts prior MI, prior stroke, qualifying symptomatic PAD, or a prior revascularization procedure.
AHI — apnea-hypopnea index, the number of apneas and hypopneas per hour of sleep. The Zepbound policy uses 15 events per hour as its documentation threshold.
MASH — metabolic dysfunction-associated steatohepatitis, a serious form of fatty liver disease with inflammation and fibrosis.

Four things that fall out of that table

1. The heart path skips a lot. If you have documented established cardiovascular disease and a baseline BMI of 27 or above, Wegovy's published cardiovascular path does not include the six-month weight program and carries a 12-month approval window instead of the eight-month adult injection weight-management window. One catch: the published path requires that the patient does not have type 2 diabetes and is receiving guideline-directed cardiovascular therapy or has a documented reason not to.Source 5

2. Zepbound's sleep-apnea path uses a different clock. The weight path uses baseline BMI. The sleep-apnea path uses current BMI. Same drug, same document, two different measurements. If you've already lost weight, that difference can determine which documented path still meets the written threshold.Source 6

3. Adult weight-management approval windows split into two groups. Wegovy tablets get six months. Wegovy standard injection, Wegovy HD, Zepbound, and Foundayo get eight. The seven-month Wegovy window in the prior draft applies to the published pediatric injection pathway, not the adult injection pathway.Source 5 Source 6 Source 7

4. The MASH path is narrower than “Wegovy injection.” Policy 4774-C allows the standard injection for this path and explicitly excludes Wegovy HD and Wegovy tablets. It also asks for F2–F3 fibrosis evidence and gastroenterology or hepatology involvement.Source 5

If you've already been on a weight-loss drug, read this

Caremark's weight-management criteria instruct reviewers to consider baseline BMI at the start of any weight-loss drug therapy when the patient is transitioning from another treatment.Source 5 Source 6 Source 7

Plain English: if you started at a BMI of 34 and you're at 28 now because a medication worked, the starting number is the one the published weight-management criteria tell the reviewer to consider.

We see people give up on coverage because they think they've "lost too much to qualify." The public policies say the earlier baseline can matter. If that's you, get the pre-medication weight and date into the request.

One honest warning about this whole section

We are not telling you to claim a condition you don't have. Every path above requires real documentation — a sleep study, cardiovascular records, liver testing, or diabetes labs. You can't talk your way in.

What we are telling you is this: your primary prescriber may not have a diagnosis or test result that sits in another specialist's record. If a cardiologist documented a qualifying event, or a sleep clinic produced an AHI result, that record can change which published criteria the office should inspect. Bring the real record into the conversation. That's the whole point.

Ready to stop guessing about your own plan?

You now have the public criteria in one place. The last piece is your specific plan — and that's the tedious part.

Ro runs a free GLP-1 Insurance Coverage Checker. Ro says it checks coverage for the Ozempic pen, Wegovy pen, and Zepbound pen and reports whether the policy requires prior authorization.Source 15

The honest limitation, so you don't waste your time: Ro's official checker page currently names only the Ozempic pen, Wegovy pen, and Zepbound pen. It does not name Foundayo, Wegovy tablets, Wegovy HD, or Zepbound KwikPen. If your drug is outside those three named products, your own plan or prescriber's office is the direct path.

The free checker is also not the same thing as joining Ro for treatment. The free tool checks coverage. If you later join Ro and an affiliated provider prescribes a supported medication when appropriate, Ro says its insurance concierge can communicate with the insurer, submit prior-authorization paperwork, and appeal a denial. Coverage is never guaranteed.Source 15 Source 16

Ro Body membership is $39 for the first month, then as low as $74/month with an annual plan paid upfront ($149/month otherwise). Medication cost is separate.Source 17

Commercial claim	What the provider states	What we verified on August 5, 2026	What it does not prove
Ro free coverage checker	Checks Ozempic pen, Wegovy pen, and Zepbound pen; reports whether PA is required	The official checker page names exactly those three pen products	That Foundayo, Wegovy tablets, Wegovy HD, or Zepbound KwikPen are checked
Ro insurance support	Insurance concierge communicates with the insurer, handles paperwork, and can appeal a denial for supported treatment	The official insurance page describes those services and says some Ro products are cash-pay only	That any request will be approved or that every Ro medication gets insurance support
Ro membership	$39 first month; $74/month annual prepay; $149 month to month	The official pricing page displays those amounts and says medication is separate	The member's medication price or insurance copay
Sesame program	As low as $59/month with a 12-month commitment; medication separate; provider choice; providers can assist with PA paperwork	The official program page displays those terms	That a particular provider accepts the member's plan or that the medication is covered

→ Check Ozempic, Wegovy, or Zepbound pen coverage with Ro (sponsored link)

Does that sound like your situation? If you'd rather your own doctor handle it, that's a completely fine answer — skip to the five-minute check below and do it yourself.

What if your plan excludes weight-loss drugs completely?

Answer: If a member plan excludes weight-management medications from the benefit, a drug-level prior authorization cannot create that missing category. Ask whether the plan offers a formal benefit appeal or exception. If it does not, the remaining paths are a different medically valid covered indication, a future benefit-design change, or FDA-approved self-pay treatment.

This is the wall. Let's be straight about it.

If your plan did not include weight-management drug coverage, more chart notes will not turn a weight-management PA into a covered benefit. Switching from Wegovy to Zepbound will not solve a category exclusion.

How to tell if this is you

Look at the exact wording:

"Prior authorization required" → not a category exclusion; obtain the criteria
"Not covered" → ambiguous; ask whether it means drug-level, form-level, or benefit-level
"Plan exclusion" or "benefit exclusion" → the benefit design may be the issue
"Weight-loss drugs are not a covered benefit under your plan" → the category itself is excluded under the wording you were given

When you call, ask this exactly: "Is weight management a covered benefit under my plan — separate from whether this drug is on the formulary? If it is excluded, does the plan offer any formal benefit appeal or exception?" That question gets you a straighter answer. "Do you cover Wegovy?" does not.

Three things that still work

1. A different documented medical indication. Go back to the five-path table. If you genuinely have documented cardiovascular disease, obstructive sleep apnea, MASH, or type 2 diabetes, the plan may evaluate the request under a different indication and policy. That is a clinician and plan question, not a workaround. Talk to your prescriber about what is actually in your records.

2. Open enrollment or a plan-design request. Ask HR or the benefits administrator whether weight-management coverage is being considered for the next plan year and where employees can submit benefit feedback. The plan sponsor, not a generic formulary article, controls that decision.

3. Paying cash for an FDA-approved product. Manufacturer-direct and telehealth cash-pay prices now vary sharply by drug, form, dose, and commitment. Do not reduce Foundayo to one flat $149 number: Lilly's current regular self-pay schedule starts at $149 for 0.8 mg and rises by dose.Source 19

Foundayo dose	Regular Lilly self-pay price for a 30-day supply, verified August 5, 2026
0.8 mg	$149
2.5 mg	$199
5.5 mg or 9 mg	$299
14.5 mg or 17.2 mg	$349 regular price; Lilly currently describes a separate $299 refill-timing purchase offer with eligibility and terms

Prices and program terms can change. Check the current manufacturer terms before making a decision.

If you've landed here and cash-pay is your reality, you want two things: an honest visit price and a real choice of prescriber.

Sesame's official program page currently advertises ongoing care as low as $59/month with a 12-month commitment; medication is separate, providers set their own prices, and the reader chooses a provider. Sesame also says providers can assist with insurance prior-authorization paperwork.Source 18

→ Compare FDA-approved cash-pay options on Sesame (sponsored link)

If you'd rather compare self-pay prices before choosing a provider, use The RX Index's GLP-1 Price & Access Tracker.

How do you check your own CVS Caremark coverage in five minutes?

Answer: Sign in to your Caremark member account and use Check Drug Cost and Coverage, searching the exact brand and form. Save the result, then call the pharmacy-benefit number on the card to separate four issues: benefit inclusion, formulary status, prior authorization, and member cost.

The lookup

Sign in to your CVS Caremark account at Caremark.com.
Open Check Drug Cost and Coverage.
Search the exact brand and form — "Wegovy" and "Wegovy tablets" are separate searches.
Enter your pharmacy and day supply if it asks.
Write down all of it: covered or not, tier, estimated cost, prior authorization, quantity limit, step therapy, listed alternatives.
Screenshot it with the date visible. You will want this later.

The phone script

Call the number on the back of your card and read this:

"I'm checking my specific pharmacy benefit, not the general CVS formulary. Is [drug name and form] covered under my plan today for [the documented indication]? Is weight management a covered benefit under my plan, separate from whether the drug is on the formulary? Does the drug require prior authorization, step therapy, or a quantity limit? What is my estimated cost at [pharmacy] for [day supply]? Is a future coverage change already loaded? Can you send the answer or restriction to me in writing?"

That last question matters more than it looks. Written answers survive. Phone calls don't.

When to call HR instead

Call your benefits team, not Caremark, if the question is about:

Whether your employer included weight-management coverage
A plan-level category exclusion
Your Summary Plan Description or other governing plan document
Whether your plan is adopting the October 1 formulary update
Whether coverage might be added at open enrollment

Caremark administers the benefit design it is given. A member-service representative cannot rewrite the benefit your plan sponsor selected.

Save these five things

Date and time · Representative name or reference number · Exact drug and form · Exact wording of any restriction or denial · Screenshot or written response.

If you end up appealing, this file gives the appeal something concrete to work with.

Use this one-page coverage-check worksheet

Field	Your answer
Plan type and plan name
Exact medication and form
Documented indication
Weight-management benefit included?
Formulary status
PA, step therapy, or quantity limit?
Exact criteria or denial reference
Estimated cost, pharmacy, and day supply
Future effective date loaded?
Representative and call reference

For a deeper walkthrough, read How to get insurance to cover a GLP-1 and GLP-1 formulary tiers explained.

What will a covered CVS Caremark GLP-1 cost?

Answer: The public formularies cannot tell you your out-of-pocket price. The member amount depends on the exact drug and form, tier, deductible status, coinsurance or copay, quantity, pharmacy, day supply, and any current manufacturer program for which you qualify. Ask for a dated estimate tied to the exact claim details.

Two things people get wrong here.

One: covered does not mean the price stays the same all year. A deductible can make an early-year fill look very different from a later fill. A pharmacy, day-supply, or form change can also change the estimate.

Two: savings programs have rules. Eligibility, maximum savings, fill limits, expiration dates, and government-benefit exclusions can change. Check the manufacturer's current terms rather than a blog's number, including ours.

Ask your plan for the estimated cost at your pharmacy, for your exact form and day supply. That's the only number that means anything for your next fill.

Why did CVS Caremark deny your GLP-1?

Answer: The denial wording identifies which gate failed. Missing documentation, an unmet clinical criterion, a nonpreferred product, step therapy, a quantity rule, and a plan-level exclusion require different responses. Filing the same generic appeal for all of them wastes time.

What the letter or portal says	What it may mean	What to do next
Prior authorization required	No qualifying approval is attached to the claim	Obtain the member-plan criteria and have the prescriber submit against that document
Criteria not met	One or more requirements were missing, unsupported, or did not match	Ask for the exact failed criterion and compare it with what was submitted
Not covered	Could mean the drug, form, or whole benefit category	Ask: drug-level, form-level, or benefit-level?
Plan exclusion	The benefit design may omit the category	Ask HR for the governing language and whether a formal plan appeal or exception exists
Nonpreferred	Another product may be preferred	Ask for the preferred alternatives and the formulary-exception standard
Step therapy	The plan requires a documented treatment sequence	Get the exact sequence and any exception standard in writing
Quantity limit exceeded	The submitted dose, quantity, or refill timing exceeds the plan rule	Confirm the prescription details and ask about the plan's override process
Continuation criteria not met	The renewal record did not show the required response or maintenance period	Compare the chart with the exact continuation criteria before resubmitting

The renewal trap

Getting approved once isn't the end. The published adult weight-management continuation criteria for Wegovy, Zepbound, and Foundayo require at least three months at a stable maintenance dose and at least 5% loss from baseline weight or continued maintenance of that initial 5% loss.Source 5 Source 6 Source 7

That's a paperwork bar. Weigh in at your appointments. Keep the baseline date, stable-dose date, and follow-up weights in the record.

The published Wegovy pediatric continuation path is different: it asks for successful titration to a stable maintenance dose and a BMI reduction or maintenance of the initial BMI reduction.Source 5

Never appeal blind

Get the written denial reason before you write a word. "Insurance denied it" isn't a reason — it's a summary. The actual reason tells you whether you need one missing record, a formulary exception, a benefit-design answer, or an entirely different strategy.

CVS Caremark GLP-1 denial decoder

My portal says “prior authorization required.”

Ask for the exact member-plan PA document and reference number. Confirm whether the request is initial or continuation, which indication is being reviewed, and whether the plan requires the six-month program. Do not submit from a generic internet checklist when the member document is available.

My portal says “not covered.”

Ask whether the problem is the exact form, a nonpreferred drug, a future effective date, or a benefit-category exclusion. Those are four different problems with four different next steps.

My letter says “criteria not met.”

Request the criterion-by-criterion decision and a copy of what the office submitted. Compare the failed line with the record. On the published weight-management policies, common evidence categories include the six-month program, baseline BMI, a qualifying comorbidity, and continuation-response records.

My letter says “plan exclusion.”

Call HR or the benefits administrator. Ask for the governing exclusion language and whether the plan has a formal appeal or exception. A new PA cannot create a category the plan did not buy.

My plan says the drug changes October 1.

Ask whether the future change is already loaded into your member benefit, whether your sponsor is adopting it, what exact effective date applies to claims, and whether a new PA will be required. Treat October 1 as a verification date, not a guaranteed fill date.

For more help with the paperwork branch, read GLP-1 providers that help with prior authorization.

What do the public CVS Caremark documents not establish?

Answer: They do not establish your exact copay, universal PA, universal coverage, or a right to use a diabetes listing for weight management. They also do not list compounded semaglutide or tirzepatide as FDA-approved formulary products. The documents answer a public baseline; the member plan answers the individual claim.

Compounded GLP-1 products

Compounded drugs are not FDA-approved. FDA does not verify their safety, effectiveness, or quality through the premarket approval process.Source 20

The public CVS Caremark formularies and PA criteria reviewed for this page do not list compounded semaglutide or compounded tirzepatide as covered FDA-approved products. That supports a narrow statement about these public documents. It does not give us access to every custom benefit contract, so we will not claim that no plan under any circumstance ever reimburses a compounded preparation.

This page answers an FDA-approved insurance-formulary question. Compounded treatment paths are not interchangeable with the FDA-approved products in the tables above, and no compounded provider belongs in the coverage recommendation on this page.

Zepbound single-dose vials

Caremark's published Zepbound policy 6192-C says the products referenced by that document include all forms and strengths except the vials, which it says are covered under the LillyDirect manufacturer program. The policy's quantity-limit table lists prefilled single-dose pens.Source 6

That is a policy-document fact, not a guarantee about your member plan. If you are searching for a vial, ask the plan and LillyDirect which payment channel applies to that exact prescription.

Diabetes GLP-1s prescribed for weight loss

The current public lists separate the diabetes incretin category from anti-obesity. Caremark's published diabetes policy 2439-C is written for type 2 diabetes and requires documented diabetes criteria.Source 8

Asking for Ozempic or Mounjaro without a documented qualifying diabetes pathway does not turn the diabetes formulary line into weight-management coverage. Use the real diagnosis, the FDA-approved indication, and the member-plan criteria. We are not going to pretend otherwise.

Published PA criteria are not member coverage

This distinction is worth repeating because it prevents the most expensive mistake on the page:

A published PA document proves that Caremark has written standard criteria. It does not prove that your plan lists the drug, includes the treatment category, or will approve your request.

How did The RX Index verify this page?

Answer: We compared CVS Caremark's July 2026 Standard Control list, July 2026 Value Formulary, October 1 future Standard Control list, four published PA policies, current FDA labels, and dated official provider-pricing pages. Where a source does not answer a question, this page says so instead of estimating.

### What we actually verified — August 5, 2026 CVS Caremark's published approval criteria, read in full:
Antidiabetic GLP-1 / GIP-GLP-1 Agonist PA with Limit, reference 2439-C
Wegovy PA with Limit, reference 4774-C
Zepbound PA with Limit, reference 6192-C
Foundayo PA with Limit, reference 7433-C
CVS Caremark's commercial drug lists: the July 1, 2026 Standard Control list, the July 1, 2026 Value Formulary, and the future-dated Standard Control list effective October 1, 2026. CVS Health's May 28, 2026 announcement on Zepbound and Foundayo. FDA labeling for the indication and form differences among Wegovy, Zepbound, Foundayo, Ozempic tablets, Rybelsus, and Mounjaro. Commercial provider pages: Ro's checker scope, insurance-concierge description, and membership pricing; Sesame's current program price and insurance-paperwork description; Lilly's current Foundayo self-pay schedule. What we did not do: we did not access anyone's member record, verify an individual copay, predict an approval decision, or confirm that every CVS Caremark client uses the same formulary. We can't, and anyone who says they can is guessing.

How we handled uncertainty

When a drug didn't appear in a published list, we wrote "not located" rather than "excluded." A public formulary is a template. Your employer or plan sponsor can customize it. The absence of a drug from a template proves the template doesn't list it — nothing more.

When Caremark published approval criteria for a drug, we did not treat that as proof of coverage. Criteria existing and your plan covering the drug are two separate facts.

When a provider described its own service or price, we labeled it as provider-stated, verified the statement on the provider's official page, and stated what the claim does not prove.

Dataset methodology

The RX Index CVS Caremark GLP-1 Coverage Map v1.0 uses one row per drug or materially different form and treatment path when the published criteria differ. For every row, we recorded:

Treatment lane
July Standard Control status
July Value Formulary status
October Standard Control status
Published PA-policy reference
Six-month-program status
Published standard initial approval window
Verification date
A note separating public-template status from member-specific coverage

The HTML table is the primary dataset. The downloadable CSV is a machine-readable copy. A future version will not overwrite the August record silently; the update log will show what changed.

Update log

Version 1.0 — August 5, 2026: Reconciled current July Standard and Value lists with the future October Standard list; added Wegovy HD; corrected adult Wegovy injection approval from seven to eight months; separated formulary status from PA-policy inclusion; verified Foundayo, Ro, Sesame, and Lilly pricing claims.
Next scheduled verification — October 1, 2026: Confirm whether the future Standard Control file became the live current file; change every future-tense Zepbound, Foundayo, and Wegovy HD statement only after that check.

Why this page exists

Because "does CVS Caremark cover it?" isn't one question. It's four questions stacked on top of each other, and a yes-or-no answer collapses them. That's how people end up making phone calls that go nowhere.

We wrote the version we'd want if it were our prescription.

Frequently asked questions about CVS Caremark GLP-1 coverage

Does CVS Caremark cover Wegovy?

Wegovy appears in the July 2026 public Standard Control list, and the July Value Formulary identifies both injection and tablet forms. Your member plan still decides whether weight-management coverage is included, which form is covered, whether restrictions apply, and what you will pay.

Does CVS Caremark cover Zepbound in 2026?

The reviewed current July Standard anti-obesity section does not list Zepbound, while the future Standard Control list adds it effective October 1, 2026. Some custom plans may differ before that date, and adoption after that date is still member-plan specific.

Will every CVS Caremark plan cover Zepbound on October 1?

No. CVS Health says plan sponsors that adopt its template formularies retain discretion to customize coverage. October 1 is a public-template effective date, not a universal member guarantee.Source 4

Does CVS Caremark cover Foundayo?

It depends on the member plan. CVS removed Foundayo's new-to-market block June 1 where plans approve coverage, Foundayo is not located in the reviewed July public lists, and it appears in the future October Standard Control list. Caremark also publishes PA policy 7433-C.Source 3 Source 4 Source 7

Does CVS Caremark cover Wegovy HD?

Wegovy HD is not located in the reviewed current July public lists. It appears in the future Standard Control list effective October 1, and Caremark's Wegovy policy 4774-C includes a weight-management pathway for the 7.2 mg injection.Source 3 Source 5

Does CVS Caremark cover Ozempic for weight loss?

The current public list places Ozempic in the diabetes category, and policy 2439-C is written for documented type 2 diabetes criteria. That listing does not prove coverage when the prescription is evaluated solely for weight management.

Why is Mounjaro listed while Zepbound is not listed right now?

Both products contain tirzepatide, but Mounjaro is the type 2 diabetes brand and Zepbound is the weight-management and obstructive-sleep-apnea brand. The public lists and PA policies evaluate them in different treatment lanes.Source 6 Source 13

Does CVS Caremark require prior authorization for every GLP-1?

The public documents do not support that universal claim. Caremark publishes PA criteria for the products analyzed here, but the July Value Formulary marks the diabetes entries with step therapy and conditional PA while the reviewed anti-obesity entries do not show a PA marker. Your member portal and plan criteria control the real answer.Source 2

How long does a CVS Caremark GLP-1 approval last?

Under the published standard criteria, adult weight-management initial approvals run six months for Wegovy tablets and eight months for Wegovy standard injection, Wegovy HD, Zepbound, and Foundayo. The Wegovy pediatric injection pathway runs seven months. Cardiovascular-risk, MASH, and diabetes paths run 12 months; Zepbound's obstructive-sleep-apnea path runs six. Member plans can differ.Source 5 Source 6 Source 7 Source 8

What BMI does CVS Caremark require?

The published adult weight-management paths use baseline BMI of 30 or higher, or 27 or higher with at least one weight-related condition. The Wegovy cardiovascular path uses baseline BMI of 27 or higher. The Zepbound sleep-apnea path uses current BMI of 30 or higher. The MASH and diabetes policies reviewed do not state a BMI threshold for those paths.Source 5 Source 6 Source 7 Source 8

I lost weight already — can my earlier BMI still count?

Possibly. The published Wegovy, Zepbound, and Foundayo weight-management criteria tell reviewers to consider baseline BMI at the start of any weight-loss drug therapy when a patient is transitioning. Put the pre-medication weight and date in the request.Source 5 Source 6 Source 7

Does a formulary listing guarantee coverage?

No. A listing tells you what appears in a public or member formulary. Benefit inclusion, the exact form, prior authorization, step therapy, quantity limits, and cost still have to be checked.

Does CVS Caremark cover compounded semaglutide or tirzepatide?

The public CVS Caremark formularies and PA criteria reviewed for this page do not list compounded semaglutide or tirzepatide as covered FDA-approved products. Compounded drugs are not FDA-approved, and the exact treatment and payment question must be handled separately.Source 20

What if my employer excluded weight-loss drugs?

A drug-level PA cannot create an excluded benefit category. Ask whether the plan offers a formal benefit appeal or exception, then discuss any genuinely applicable alternate indication with your prescriber or compare FDA-approved self-pay paths.

Does this page apply to Medicare, Medicaid, or FEHB plans that use Caremark?

Not automatically. This page analyzes public commercial Standard Control and Value documents. Medicare, Medicaid, FEHB, and other plan types require their own formulary, Evidence of Coverage, and criteria.

What does Ro's free GLP-1 insurance checker cover?

Ro's official checker currently names the Ozempic pen, Wegovy pen, and Zepbound pen. It does not currently name Foundayo, Wegovy tablets, Wegovy HD, or Zepbound KwikPen.Source 15

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.

You'll get a personalized action plan for your situation — which treatment path to investigate, which coverage document to check, and exactly what to verify first.

→ Start the free quiz — no account, no card, 60 seconds.

Primary sources

Related guides

This page is for information, not medical advice. Do not start, stop, switch, or delay a prescription based on this page. Coverage rules, criteria, provider services, and prices change. Confirm the current answer with your plan and prescriber.